Balyasny Asset Management
KYTX icon

Balyasny Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

Balyasny Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.71M Buy
1,125,321
+144,452
+15% +$1.2M 0.01% 1042
2025
Q4 		$9.22M Buy
+980,869
New +$7.28M 0.01% 1066
2024
Q4 		– Sell
-33,308
Closed -$163K – 3350
2024
Q3 		$163K Buy
+33,308
New +$257K ﹤0.01% 2597
2024
Q2 		– Sell
-16,721
Closed -$415K – 3199
2024
Q1 		$415K Buy
+16,721
New +$467K ﹤0.01% 2122

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's KYTX Position: Q1 2026 in Review

Balyasny Asset Management increased its Kyverna Therapeutics (KYTX) stake by 15% in Q1 2026, buying an estimated $1.2M and bringing the position to 1,125,321 shares worth $9.71M. The position accounts for 0.01% of the portfolio, ranked #1042.

Balyasny Asset Management first reported a position in KYTX in Q1 2024 and has held it in 4 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Balyasny Asset Management held 1,125,321 shares of Kyverna Therapeutics worth $9.71M as of Q1 2026.
  • Balyasny Asset Management bought 144,452 Kyverna Therapeutics shares in Q1 2026, an estimated $1.2M.
  • Kyverna Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1042 holding.
  • Balyasny Asset Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.